Example: Heart Attack

Clinical Trials on Glabellar Crease

Total 10000 results

NCT02607215

Recruiting

Platinum Rechallenge in Patients With Platinum-sensitive mTNBC

Metastatic Breast Cancer
NCT06968585

Active, not recruiting

A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy (A166)

HER2-positive Breast Cancer
NCT03975647

Active, not recruiting

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

HER2-positive Breast Cancer
NCT03747042

Completed

Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer

Breast Cancer Female
NCT07371910

Active, not recruiting

Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer

Metastatic Breast Cancer | HRD-Positive/HER2-Negative Advanced Breast Cancer
NCT06533670

Active, not recruiting

TME Alteration in HER2 Positive Breast Cancer

Breast Cancer | HER2-positive Breast Cancer | Chemotherapy Effect
NCT05529862

Active, not recruiting

Trans-RosaLEE Study: a Biomarker-directed, Translational Study (TransRosaLEE)

Advanced or Metastatic Breast Cancer (BC)
NCT05599334

Completed

A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib (NEAR)

Breast Cancer | HER2-positive Breast Cancer | Adjuvant Therapy
NCT06316531

Active, not recruiting

A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

HER2-positive Breast Cancer
NCT06914661

Enrolling by invitation

Efficacy and Safety of DS8201 in Metastatic Breast Cancer's Treatment (EASOFDIMBCT)

Breast Cancer Metastatic | Efficacy and Safety
NCT05054751

Completed

GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

Locally Advanced or Metastatic Breast Cancer
NCT01874522

Completed

Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI

Advanced Solid Tumors (Excluding Breast Cancer)
NCT05690295

Completed

Resistance-type Exercise Training in Postmenopausal Women Survivors of Breast Cancer (MUSCLE-CLIM)

Resistance Training | Postmenopause | Breast Cancer Survivors
NCT05723237

Active, not recruiting

The Effect of Breast Cancer Screening Training

Women's Health: Neoplasm of Breast
NCT02489448

Completed

Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer

Breast Neoplasms
NCT04396665

Completed

Breast Cancer: Feasibility of an Educational Intervention (PRECAM-2)

Women's Health: Neoplasm of Breast
NCT03939871

Unknown

A Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer

Hormone Receptor Positive Advanced Breast Cancer
NCT01049425

Completed

Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer (planB)

Primary Breast Cancer | Her2 Non-overexpressing
NCT03131011

Terminated

Body-image Satisfaction Following Permanent Black or Invisible UV Ink Tattoos (SPOT)

Body Image Disturbance | Breast Cancer Female
NCT03925233

Unknown

Breast Cancer Treatment Based on Organ-like Culture

Breast Cancer Organoids
NCT03437083

Completed

A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants

Locally Advanced or Metastatic Breast Cancer
NCT00634088

Terminated

Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Locally Advanced or Metastatic Breast Cancer
NCT01329627

Terminated

Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast Cancer (TAME-01)

Locally Advanced HER2-negative Breast Cancer
NCT01329640

Terminated

Feasibility Study of Metronomic Chemotherapy for Locally Advanced Her2- Positive Breast Cancer (TraQ-Me 01)

Locally Advanced HER2-positive Breast Cancer
NCT01943032

Completed

Discordant Hormonal Status of Breast Cancer.

Malignant Neoplasm of Breast.
NCT01630226

Unknown

Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland

BRCA1 Mutation | Breast Cancer Invasive Nos
NCT07601178

Recruiting

QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer

TNBC, Triple Negative Breast Cancer
NCT07551050

Recruiting

Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer

TNBC - Triple-Negative Breast Cancer
NCT07523789

Not yet recruiting

Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC

TNBC, Triple Negative Breast Cancer
NCT07513311

Not yet recruiting

A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer (RESTORE)

Triple Negative Breast Cancer (TNBC)
NCT07428018

Not yet recruiting

Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib (VIOLET)

Breast Cancer | Neoadjuvant Therapy | HR Positive | HER2 + Breast Cancer
NCT07413601

Not yet recruiting

Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer Metastatic
NCT07394387

Recruiting

Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.

Triple Negative Breast Cancer (TNBC)
NCT07256964

Not yet recruiting

Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer

TNBC - Triple-Negative Breast Cancer
NCT07206394

Recruiting

Feasibility Trial of ScarWork for Post-breast Surgery Pain Syndrome.

Breast Cancer Early Stage Breast Cancer (Stage 1-3)
NCT07187674

Not yet recruiting

The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel

Triple Negative Breast Cancer (TNBC)
NCT07097155

Recruiting

Avocado Consumption and Cellular Aging in Breast Cancer Survivors (ACCA)

Breast Cancer Females | Telomere Length
NCT06966141

Recruiting

A Real World Study of Sacituzumab Govitecan

Breast Cancer Metastatic | Treatment Outcome
NCT06928701

Recruiting

Impact of "Targeted" Nutritional Apport and Exercise on the Modulation of Metabolic and Immune-related Gene Expression Signatures in Early Breast Cancer (eBC) Patients Candidate to Neoadjuvant Therapy (NAT) (NEOMET)

Early Breast Cancer | Neoadjuvant Treatment
NCT06797531

Recruiting

RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia (NISLEESA)

HR+/HER2- Early Breast Cancer
NCT06729684

Recruiting

Development and Validation of a Personalized Digital Healthcare Model for Managing Side Effects in Breast Cancer Survivors

Breast Cancer | Digital Health | Breast Cancer Survivorship
NCT06711094

Not yet recruiting

Albumin-bound Paclitaxel、Dalpiciclib and AI in ER-Low (1%-10%) HER2-ABC

HR+/HER2- Advanced Breast Cancer
NCT06663748

Not yet recruiting

ARX788 in HER2-positive Metastatic Breast Cancer Patients

HER2-positive, Metastatic Breast Cancer
NCT06583460

Recruiting

Systematic Intervention to Improve Sexual Dysfunction (SISTER)

Breast Cancer Female | Localized Cancer
NCT06435429

Recruiting

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

Metastatic HER2-positive Breast Cancer
NCT06167694

Recruiting

Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer

Unresectable or Metastatic Breast Cancer
NCT05871918

Recruiting

A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer

HER-2 Positive Breast Cancer
NCT05483439

Recruiting

A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer

Stage II-III Breast Cancer
NCT05245812

Recruiting

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

Breast Cancer | High Risk of Breast Cancer
NCT05187832

Recruiting

A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

Advanced or Metastatic Breast Cancer

Clinical Trials on Glabellar Crease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations